XenoPort And GlaxoSmithKline Report Positive Top-line Results Of Final Pivotal Trial Of XP13512/
XenoPort And GlaxoSmithKline Report Positive Top-line Results Of Final Pivotal Trial Of XP13512/
|
XenoPort, Inc. (Nasdaq: XNPT) and GlaxoSmithKline (NYSE: GSK) announced positive top-line results from the final pivotal Phase 3 clinical trial of XP13512 (GSK1838262) for the treatment of moderate-to-severe symptoms of primary restless legs syndrome, or RLS. |
read more...
News entry number 4147 added on Mar 3, 2008 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- Memory Pharmaceuticals Announces Positive Phase 2a Results For MEM 3454 In Alzheimer's Disease
- A nation expects as Laporte's blueprint faces final test
- U.S., Argentina advance to FIBA Americas final
- Clavis Pharma ASA To Present Phase I Clinical Results From ELACYT In Patients With Cancers Of The Bl
- Computerworld Reviews Database Search Results
- Final note comes early for rockers
- Ravens 20, Jets 13: A Final Possession Shows Promise but Ends With a Jets Loss
- Sony Ericsson Championships: Sharapova sweeps into final for dream match-up with world No 1
- 'A huge game and a fabulous final'
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Wireless technology hits security budgets
- Google forced to push image in China
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
- Ho-hum, the guest's another candidate
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Microsoft purchase of RIM nice to consider, but unlikely
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
610
8
610